In B16-F10 melanoma models, c-di-GMP-PNT significantly upregulated IFN-β, TNF-α, IL-6, and IL-1β expression, activated CD4+/CD8+ T cells, and enhanced tumor cell killing (87). This evidence concerns the gene CD8A and melanoma.